C ancer often becomes lethal only when cells from the primary tumour disseminate to another organ. The early steps of this highly complex process, called metastasis, have been thought 1 to rely on non-motile epithelial tumour cells acquiring characteristics of mesenchymal cells, which are more migratory. This change is known as the epithelial-to-mesenchymal transition (EMT). The migrating cancer cells then undergo a reverse mesenchymal-to-epithelial transition when they seed a secondary tumour 2 . Metastases therefore display the same epithelial-cell predominance as primary cancers, leaving no evidence of their transient mesenchymal state. Now, two papers in this issue (Fischer et al. 3 and Zheng et al. 4 ) present data that challenge the role of EMT as a crucial effector of cancer metastasis.
In terms of cancer-cell characteristics, the epithelial lineage is associated with increased proliferation, whereas the mesenchymal lineage is linked to enhanced avoidance of anoikis (a form of death that occurs when cells detach from their normal tissue matrix) and of drug-induced death. Current understanding of EMT-induced metastasis is derived from in vitro data and mouse models of human cancers. But the inherent plasticity of the process and the limited clinical evidence supporting the occurrence of EMT in tumour specimens 2, 5 have led to scepticism about EMT being the predominant mechanism governing the early steps of metastasis. EMT is, however, emerging as one of numerous mechanisms conferring resistance to various cancer therapies 6 . Using mouse models of mammary tumours, Fischer and co-workers (page 472) surveyed the fate of epithelial tumour cells transitioning to a mesenchymal state, from the cells' inception and dissemination through the bloodstream to their exit from blood vessels and metastatic growth. To do this, the authors monitored the expression of green fluorescent protein (GFP) as a proxy for the expression of the genes that encode fibroblast-specific protein 1 (FSP1) or vimentin, which are triggered when epithelial tumour cells switch to a mesenchymal state. The green fluorescence persists in the progeny of these cells well after they revert to an epithelial fate.
In two mouse models, the authors found evidence for EMT in a minor fraction of cells in the primary tumour and in a subset of circulating tumour cells. However, the vast majority of metastatic tumours were not derived from the mesenchymal-switched cells expressing GFP, but from disseminating epithelial cells (Fig. 1) . The researchers further show that inhibiting expression of the genes ZEB1 and ZEB2, which locks tumour cells in the epithelial state, did not impair metastasis of the mouse mammary tumours to the lung.
Zheng et al. (page 525) reached a similar conclusion using tissue-specific deletion of the EMT-inducing transcription factors Snail or Twist to assess the consequences of EMT in a mouse model of pancreatic cancer. They found that loss of either Snail or Twist in the pan creatic epithelium does not affect tumour formation or overall survival, but it does suppress EMT in the primary tumour. Despite the lower frequency of cells expressing mesenchymal marker proteins in these tumours compared with those in mice in which Snail and Twist are expressed at normal levels, there were a similar number of metastases in the liver, lungs and spleen of these mice.
Although they question the role of EMT in metastatic dissemination, both research groups go on to conclude that EMT contributes to drug resistance. In Fischer and colleagues' mammary-tumour model, treatment with the drug cyclophosphamide led to enhanced survival and proliferation of In 2013, researchers achieved superresolution ultrasound imaging by using a sufficiently dilute solution of microbubbles to achieve the necessary separation 2 . Earlier this year, the same group used this approach to obtain super-resolution images of the microvasculature in a mouse ear to a depth of more than one centimetre 3 . They also tracked the microbubbles, to estimate blood-flow velo city. However, their system acquired images at the low rate of 25 frames per second, which meant that hour-long imaging times were needed to achieve super-resolution.
Errico et al. used a different approach that dispensed with the need for a dilute microbubble solution. By using a high-frame-rate imaging system (500 frames per second), they were able to detect the waves scattered from individual microbubbles by comparing sequential images. Signals from bubbles that have disintegrated or moved significantly in the time between frames can be detected in the data, and -as long as these changes are sparse enough to be spatially separated from one another -the positions and velocities of these microbubbles can be accurately determined 4, 5 ( Fig. 1) . The authors compared 75,000 images taken over about 150 seconds to build up super-resolution images of the vasculature in the cortical region of rat brains, through both intact rat skulls and skulls that had been thinned to reduce the acoustic attenuation.
Could this technique be translated to a clinical setting? At the ultrasound wavelengths used by Errico and colleagues, overcoming the attenuating effect of the thick human skull will present a considerable challenge. The authors point out that it might be possible to circumvent this problem by using longer wavelengths, which are less severely attenuated. None theless, imaging of less-challenging targets that do not require the ultrasound waves to pass through thick bone should be readily achievable. One disadvantage of the new approach compared with conventional ultrasound imaging is the need to administer a contrast agent; this requires an intravenous cannula and can increase clinical scanning time.
Super-resolution ultrasound imaging of microvasculature is an exciting prospect. EMT-switched tumour cells that had reached the lung. Analysis of the genes being expressed in these cells correlated this resistance with increased expression of genes encoding drugmetabolizing enzymes and drug-transporter proteins. These findings were mirrored in Zheng and colleagues' Snail-or Twist-deleted pancreatic cancers, in which tumour cells with epithelial characteristics expressed higher levels of nucleoside-transporter proteins than did mesenchymal cells, potentially rendering the epithelial cells more sensitive to the chemotherapeutic drug gemcitabine. These findings challenge the prevailing hypothesis that EMT is a key element in the metastatic dissemination of epithelial cancers, and they point to a distinct role of this cell-fate transition in enhancing cancer-cell survival during drug treatment. How can these data be reconciled with compelling previous reports on the role of EMT in metastasis? The earlier work studied the effects of EMT induced by the growth factor TGFβ or by overexpression of transcriptional regulators such as Snail or Twist. Such approaches might not capture the physiological process that occurs spontaneously in cancer cells as accurately as do the methods used in the current studies. It is probable that the induction of EMT that occurs during the natural progression of a cancer may be more subtle than the full EMT switch that is induced by the expression of powerful regulators and that has been associated with high levels of metastasis.
However, the limitations of the models used by Fischer et al. and Zheng et al. need to be considered before EMT-mediated tumour invasion can be dismissed outright. EMT is orchestrated by complex circuitry involving multiple signalling molecules and transcription factors. Tracing switched cells on the basis of expression of a single gene may therefore not fully capture these complicated features. Similarly, Snail and Twist function redundantly in many settings 2, 7, 8 , and inactivation of both (and potentially of other transcriptional regulators) simultaneously, rather than individually, may 3 and Zheng et al. 4 find that the majority of metastatic tumours at secondary sites are initiated by epithelial cells from the primary tumour, and not by cells that have undergone EMT and subsequent MET. However, both research groups also show that such transitioned cells are more resistant to chemotherapeutic drugs than are untransitioned epithelial cells and emerge as the dominant metastatic population following treatment.
be required to abrogate EMT. Furthermore, cancer is a highly variable disease, and its full complexity cannot be completely captured in mouse models that are driven by expression of a few cancer-initiating genes. Nonetheless, the conclusions reached by the two studies warrant a re-evaluation of the role of EMT in cancer progression. Alternative ways in which epithelial cells could enter the bloodstream without acquiring mesenchymal properties, such as collective epithelial-cell migration 9 or tumour fragmentation 10 , are worth investigating. The postulated role of EMT in mediating cancer-cell survival is reinforced by the two latest studies. Indeed, EMT has been linked to drug susceptibility of cancer cells, as well as to their entrance into a non-proliferative state in which they have stem-cell-like properties 11 . Understanding the many cellular pathways that together determine these cell fates, and how these pathways are modulated, is likely to provide fertile ground for drug discovery and for new therapeutic strategies. ■ 
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